Spectral AI (Spectral AI) Growth Rank : 0 (As of Jun. 09, 2024)

View and export this data going back to 2023. Start your Free Trial

What is Spectral AI Growth Rank?

Spectral AI has the Growth Rank of 0.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Spectral AI Growth Rank Related Terms

Thank you for viewing the detailed overview of Spectral AI's Growth Rank provided by GuruFocus.com. Please click on the following links to see related term pages.

Spectral AI (Spectral AI) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Spectral AI Inc (NAS:MDAI) » Definitions » Growth Rank

Comparable Companies

Traded in Other Exchanges

N/A

Address

2515 McKinney Avenue, Suite 1000, Dallas, TX, USA, 75201

Website

https://www.spectralmd.com

Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely and informed decision regarding the treatment of the patient's wound.

Executives

John Michael Dimaio	10 percent owner	6125 LUTHER LANE, DALLAS TX 75225
Michael Patrick Murphy	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Els 1960 Family, L.p.	10 percent owner	2323 VICTORY AVE., SUITE. 700, DALLAS TX 75219
Richard John Cotton	director	RUE DU VILLAGE 4, CHAMPERY V8 1874
Mellish Martin C.b.	director	13 BERRILL FARMS LN, HANOVER NH 03755
Jeffrey Edward Thatcher	officer: Chief Scientist	6659 ESCONDIDO ST, IRVING TX 75039
Nils Windler	officer: Chief Financial Officer	8602 NAPA LANDING, SAN ANTONIO TX 78015
Wensheng Fan	director, officer: CHIEF EXECUTIVE OFFICER	3320 SPRING MOUNTAIN DRIVE, PLANO TX 75025
Vincent S. Capone	officer: GENERAL COUNSEL	1620 GRASSHOPPER LANE, LOWER GWYNEDD PA 19002
Nikolaos Pagoulatos	officer: CHIEF OPERATING OFFICER	5122 IROQUOIS DR, FRISCO TX 75034
Xiaojia Cynthia Cai	director	10 CELESTIAL WAY, NEWARK DE 19711
Heather Bellini	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Edmonds Franklin S. Jr.	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Rosecliff Acquisition Sponsor I Llc	director	767 FIFTH AVENUE, 34TH FLOOR, NEW YORK NY 10153
Erich Spangenberg	10 percent owner	73 595 EL PASEO, SUITE 2204, PALM DESERT CA 92260